Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Oct 17, 2011 (15 years ago)

Prefera OB One Gel Capsules

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Labeling: Presence of Undeclared Color Additive; The product is being recalled because several inactive ingredients were not included in the labeling for this product: Undeclared D&C Red #33, FD&C Blue #1, Titanium Dioxide Suspension, Purified Water USP.

Cause type: Labeling / mix-up

Wrong label, wrong strength, mixed-up products, or packaging errors. One of the most dangerous causes - you can end up taking the wrong drug or the wrong dose. All labeling / mix-up recalls.

What was recalled

Prefera OB One Gel Capsules, 30 softgels, Rx Only, Manufactured by: IVC industries, Inc. Irving ton, NJ 07111, For: Alaven Pharmaceutical LLC Marietta, GA 30062, NDC 68220-086-30

Affected NDC 68220-0086-30

Compare with the code on your package — it is the most precise check available.

Recalling firm
Meda Pharmaceuticals Inc.
NDC code
68220-086-30
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1418-2012 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other labeling / mix-up recalls from 2011

All labeling / mix-up recalls
Class II · Moderate risk

Docusate Calcium Softgel Capsules

Labeling: Label Mix up; product labeled to contain Docusate Sodium 240mg instead of Docusate Calcium 240mg

Terminated Labeling / mix-up Shamrock Medical Solutions Group LLC NDC 00904-5779-60 D-1451-2014
Class II · Moderate risk

Sulfamethoxazole and Trimethoprim Tablets

Labeling: Label Mix up; product labeled to contain Sulfamethoxazole and Trimethoprim Tablets, 400 mg/80 mg instead of Sulfamethoxazole and Trimethoprim Tablets, 800 mg/160 mg

Terminated Labeling / mix-up Shamrock Medical Solutions Group LLC NDC 53746-272-01 D-1450-2014
Class II · Moderate risk

Pramipexole Dihydrochloride Tablets

Labeling: Label Mix up; product labeled to contain Nebivolol tablets actually contained Pramipexole Dihydrochloride tablets

Terminated Labeling / mix-up Shamrock Medical Solutions Group LLC NDC 16714-586-01 D-1449-2014
Class I · High risk

metFORMIN ER Tablets

Labeling: Label Mix up; product labeled did not indicated Extended Release

Terminated Labeling / mix-up Shamrock Medical Solutions Group LLC NDC 53746-178-01 D-1448-2014